Ieq Capital LLC Trims Holdings in Kenvue Inc. $KVUE

Ieq Capital LLC cut its stake in Kenvue Inc. (NYSE:KVUE) by 7.9% in the 1st quarter, Holdings Channel.com reports. The firm owned 11,833 shares of the company’s stock after selling 1,020 shares during the quarter. Ieq Capital LLC’s holdings in Kenvue were worth $284,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in shares of Kenvue by 4.9% in the first quarter. Vanguard Group Inc. now owns 229,144,387 shares of the company’s stock valued at $5,494,882,000 after purchasing an additional 10,600,682 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Kenvue by 2.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 25,606,238 shares of the company’s stock valued at $613,882,000 after purchasing an additional 633,461 shares in the last quarter. Boston Partners grew its position in shares of Kenvue by 7.4% in the first quarter. Boston Partners now owns 25,346,453 shares of the company’s stock valued at $606,920,000 after purchasing an additional 1,750,490 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Kenvue by 11.6% in the first quarter. JPMorgan Chase & Co. now owns 24,912,226 shares of the company’s stock valued at $597,395,000 after purchasing an additional 2,597,920 shares in the last quarter. Finally, Starboard Value LP purchased a new position in shares of Kenvue in the fourth quarter valued at $467,864,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Trading Down 9.3%

Shares of KVUE stock opened at $18.64 on Friday. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The business has a 50-day moving average price of $21.37 and a two-hundred day moving average price of $22.38. Kenvue Inc. has a 12-month low of $17.15 and a 12-month high of $25.17. The firm has a market cap of $35.76 billion, a P/E ratio of 25.18, a price-to-earnings-growth ratio of 2.95 and a beta of 0.83.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.94 billion. During the same quarter in the previous year, the company posted $0.32 earnings per share. The company’s revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were paid a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.5%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. Kenvue’s dividend payout ratio is presently 112.16%.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Citigroup dropped their price objective on Kenvue from $24.50 to $22.00 and set a “neutral” rating for the company in a research note on Tuesday, July 15th. Canaccord Genuity Group dropped their price objective on Kenvue from $29.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, August 8th. UBS Group dropped their price objective on Kenvue from $25.00 to $23.00 and set a “neutral” rating for the company in a research note on Thursday, July 17th. JPMorgan Chase & Co. dropped their price objective on Kenvue from $27.00 to $26.00 and set an “overweight” rating for the company in a research note on Friday, July 25th. Finally, Barclays dropped their price objective on Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a research note on Tuesday, July 15th. Five equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $24.38.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.